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The objective of this study was to investigate the potential role of ceftaroline, a new broad-spectrum
cephalosporin, as a therapeutic option for the treatment of daptomycin-nonsusceptible (DNS) methicillin-
resistant Staphylococcus aureus (MRSA) infections. Four clinical DNS MRSA strains, R5717, R5563, R5996
(heteroresistant vancomycin-intermediate S. aureus) and R5995 (vancomycin-intermediate S. aureus) were
evaluated in a two-compartment hollow-fiber in vitro pharmacokinetic/pharmacodynamic model at a starting
inoculum of 107 CFU/ml for 96 h. Simulated regimens were ceftaroline at 600 mg every 12 h (q12h) (maximum
free-drug concentration [fCmax], 15.2 g/ml; serum half-life [t1/2], 2.3 h), daptomycin at 6 mg/kg q24h (fCmax,
7.9 g/ml; t1/2, 8 h), and daptomycin at 10 mg/kg q24h (fCmax, 15.2 g/ml; t1/2, 8 h). Differences in CFU/ml
between 24 and 96 h were evaluated by analysis of variance with Tukey’s post-hoc test. Bactericidal activity was
defined as a >3-log10 CFU/ml decrease in the colony count from the initial inoculum. The ceftaroline MIC
values were 0.25, 0.5, 0.5, and 0.5 g/ml, and the daptomycin MIC values were 2, 2, 4, and 4 g/ml for R5717,
R5563, R5996, and R5995, respectively. Ceftaroline displayed sustained bactericidal activity against 3 of the 4
strains at 96 h (R5717, 3.1 log10 CFU/ml; R5563, 2.5 log10 CFU/ml; R5996, 5.77 log10 CFU/ml; R5995,
6.38 log10 CFU/ml). Regrowth occurred during the daptomycin at 6-mg/kg q24h regimen (4 strains) and the
daptomycin at 10-mg/kg q24h regimen (3 strains). At 96 h, ceftaroline was significantly more active, resulting
in CFU/ml counts lower than those obtained with daptomycin at 6 mg/kg q24h (4 strains, P < 0.008) and
daptomycin at 10 mg/kg q24 h (3 strains, P < 0.001). Isolates with increased MIC values for daptomycin (all
4 strains) but not for ceftaroline were recovered. Ceftaroline was effective against the 4 isolates tested and may
provide a clinical option for the treatment of DNS MRSA infections.
Daptomycin (DAP)-nonsusceptible (DNS) Staphylococcus
aureus is defined as a strain having an MIC of 1 g/ml (5). In
North America, the rate of DNS S. aureus is 0.01 to 0.1%, with
no trend of increasing MIC values observed over the past
several years (4, 27, 29, 33). DNS S. aureus infections occur
mainly in patients with high-inoculum infections requiring
long-term treatment such as osteomyelitis, medical devices,
septic arthritis, or endocarditis (3, 35). Bactericidal therapies
with a favorable safety profile are preferred to treat these types
of infections. The recent guidelines from the Infectious Dis-
eases Society of America for the treatment of methicillin-
resistant S. aureus (MRSA) list telavancin, linezolid, tri-
methoprim-sulfamethoxazole, and quinupristin-dalfopristin as
potential therapeutic options for the treatment of DNS S.
aureus infections (19). Unfortunately, some of these agents and
most other available alternative antistaphylococcal antibiotics,
including tigecycline, clindamycin, and the tetracyclines, are
typically bacteriostatic or may be limited by safety concerns.
The optimal therapy for the treatment of infections caused by
DNS S. aureus infections is therefore currently unknown (19,
35). Since the area under the concentration-time curve (AUC)/
MIC or peak/MIC ratio is the pharmacodynamic parameter
that best predicts efficacy, a “high dose” of DAP of 8 to 12
mg/kg/day has been evaluated clinically, showing both efficacy
and a favorable safety profile (11, 22, 24). For this reason,
high-dose DAP (10 mg/kg/day) is included in the recent MRSA
guidelines to treat a variety of infections (19).
Ceftaroline (CPT), the active form of the prodrug CPT
fosamil, is a novel broad-spectrum cephalosporin approved by
the United States Food and Drug Administration in 2010 for
the treatment of community-acquired bacterial pneumonia
and acute bacterial skin and skin structure infections. The
current FDA-approved breakpoint for CPT against S. aureus
(skin infections only) is 1 g/ml (12). Similar to the mecha-
nism of action of other cephalosporins, CPT binds to penicil-
lin-binding proteins (PBPs), leading to inhibition of cell wall
synthesis (17, 23, 40). CPT displays activity against many
Gram-positive pathogens, including Staphylococcus spp. and
Streptococcus spp. (10, 14, 15, 20, 25, 26, 30–32, 34). CPT has
a strong affinity for PBP1, -2, and -3 and also maintains affinity
for PBP2a, which is present in MRSA and confers resistance to
methicillin and most other -lactams (23, 40). In addition, CPT
appears to maintain its susceptibility profile against strains of
S. aureus displaying reduced susceptibility to vancomycin and
DAP, including vancomycin-intermediate S. aureus (VISA),
heteroresistant VISA (hVISA), vancomycin-resistant S. au-
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reus, and DNS S. aureus, as evidenced by MIC50 values of 0.5
g/ml for DNS S. aureus (31, 34). CPT displays a favorable
safety profile similar to those of other cephalosporins, with
most adverse effects being mild (37, 41).
The objective of the present study was to investigate the
potential of CPT as a therapeutic option for the treatment of
DNS MRSA infections by using an in vitro pharmacokinetic/
pharmacodynamic (PK/PD) model.
(This study was presented as an oral presentation at the 21st
European Congress of Clinical Microbiology and Infectious
Diseases/27th International Congress of Chemotherapy, Mi-
lan, Italy, 2011.)
MATERIALS AND METHODS
Bacterial strains. A total of four clinical isolates of DNS MRSA obtained from
patients with bacteremia at the Detroit Medical Center were evaluated, i.e.,
R5717, R5563, R5996 (hVISA), and R5995 (VISA). All isolates were tested by
the previously described modified population analysis profile method using Mu3
as a control strain to determine hVISA or VISA status (42).
Antimicrobials and media. CPT (lot no. FMD-CEF-019 and FMD-CEF-028)
was provided by its manufacturer (Forest Laboratories, Inc., New York, NY).
CPT solutions were prepared daily in 50% dimethyl sulfoxide and 50% sterile
water. DAP was commercially purchased. Mueller-Hinton broth II (MHBII;
Difco, Detroit, MI) with 25 mg/liter calcium and 12.5 mg/liter magnesium was
used for MIC testing and in vitro PK/PD models with CPT. MHBII supple-
mented to 50 mg/liter of calcium was used for MIC testing, and in vitro PK/PD
models were used to evaluate DAP simulations due to the dependency of DAP
on calcium for antimicrobial activity (18). Colony counts were determined using
Tryptic Soy Agar (TSA; Difco, Detroit, MI) plates. Development of resistance
was evaluated using either Mueller-Hinton agar (MHA; Difco, Detroit, MI)
supplemented with 50 mg/liter of calcium or brain heart infusion agar (Difco,
Detroit, MI) plates containing DAP and CPT, respectively.
Susceptibility testing. MIC values were determined by broth microdilution at
106 CFU/ml according to CLSI guidelines (5). All samples were incubated at
35°C for 24 h.
In vitro PK/PD model. A previously described in vitro PK/PD model consisting
of a two-compartment hollow-fiber model chamber (Fiber Cell Systems, Inc.,
Frederick, MD) with multiple ports for the addition and removal of growth
medium, delivery of antibiotics, and collection of samples was used (39). Due to
differences in the DAP penetration of various fiber model cartridges, a cellulosic
fiber cartridge (C3008; Fiber Cell Systems, Inc., Frederick, MD) was utilized for
all experiments with DAP and CPT. The apparatus was prefilled with medium,
and antibiotics were administered as boluses over a 96-h time period. Prior to
each experiment, several colonies from an overnight growth on TSA were sus-
pended and added to each model to obtain a starting inoculum of 107 CFU/ml.
Fresh medium was continuously supplied to and removed from the central
compartment along with the drug via a peristaltic pump (Masterflex; Cole-
Parmer Instrument Company, Chicago, IL) set to simulate the human half-lives
(t1/2) of the antibiotics. The antibiotic regimens evaluated included CPT simu-
lations of 600 mg every 12 h (q12h; maximum free-drug concentration [fCmax],
15.2 g/ml; t1/2, 2.3 h; protein binding, 20%) and DAP simulations of 6 mg/kg
q24h (DAP6; fCmax, 7.9 g/ml; t1/2, 8 h; protein binding, 93%) and 10 mg/kg q24h
(DAP10; fCmax, 13.17 g/ml; t1/2, 8 h; protein binding, 93%) (2, 13). All models
were done in duplicate to ensure reproducibility.
Pharmacodynamic analysis. Samples from each model were collected at 0, 2,
4, 8, 24, 32, 48, 56, 72, and 96 h and diluted in cold 0.9% saline. Colony counts
were determined by spiral plating appropriate dilutions using an automatic spiral
plater (WASP; DW Scientific, West Yorkshire, England) to enumerate the
CFU/ml. Colonies were counted using a laser colony counter (ProtoCOL; Syn-
optics Limited, Frederick, MD). If the drug concentration at the anticipated
dilution was within 1 tube dilution of the MIC or higher, then vacuum filtration
was used to avoid antibiotic carryover. When vacuum filtration was used, samples
were washed through a 0.45-m filter with normal saline to remove the antimi-
crobial agent and recover the bacteria on the filter, which was then placed on
TSA plates. For both methods, plates were incubated at 37°C for 24 h, after
which colony counts were performed. These methods have a lower limit of
reliable detection of 1 log10 CFU/ml. The total reduction in log10 CFU/ml over
96 h was determined by plotting time-kill curves based on the number of re-
maining organisms. Bactericidal activity (99.9% killing) was defined as a 3-
log10 CFU/ml decrease in the colony count from the initial inoculum. Bacterio-
static activity was defined as a 3-log10 CFU/ml reduction in the colony count
from the initial inoculum, and inactivity was defined as no observed reduction of
the initial inoculum. The time required to achieve a 99.9% bacterial load reduc-
tion was determined by linear regression or by visual inspection (if r2 was 0.95).
Antibiotic activity was assessed at every time point.
Pharmacokinetic analysis. Pharmacokinetic samples were obtained through
the injection port of each model at 0.5, 1, 2, 4, 8, 24, 32, 48, 56, 72, and 96 h in
duplicate for the verification of target antibiotic concentrations. All samples were
stored at 70°C until ready for analysis. CPT and DAP concentrations were
determined by bioassay. For CPT, blank 0.25-in. disks were placed on pre-
swabbed (Bacillus subtilis ATCC 6633) agar plates (antibiotic medium number
11) and spotted with 10 l of the standards (2.5, 10, and 40 g/ml) or samples.
For DAP, 0.25-in. holes were punched in preswabbed (Micrococcus luteus ATCC
9341) agar plates (antibiotic medium number 5) and filled with 50 l of the
standards (2.5, 7.5, and 15 g/ml) or samples. Each standard and sample was
tested in duplicate. Plates were incubated for 18 to 24 h at 37°C, at which time
the zone sizes were measured using a protocol reader (Protocol; Microbiology
International, Frederick, MD). The t1/2, fCmax, and fCmin of CPT and DAP were
determined from the concentration-versus-time plots. The time above the MIC
was calculated using first-order elimination concepts. The area under the con-
centration-time curve (AUC) and the subsequent AUC/MIC ratio were deter-
mined by the trapezoidal method utilizing PK Analyst Software (version 1.10;
MicroMath Scientific Software, Salt Lake City, UT).
Resistance. Development of resistance was evaluated at multiple time points
throughout the simulation at 24, 48, 72, and 96 h. A sample (100 l) from each
time point was plated on MHA or brain heart infusion plates supplemented with
3  MIC DAP or CPT to assess the development of resistance. Plates were then
examined for growth after 24 and 48 h of incubation at 35°C.
Statistical analysis. Changes in the number of CFU/ml at 24, 48, 56, 72, and
96 h were compared by two-way analysis of variance with Tukey’s post-hoc test.
A P value of 0.05 was considered significant. All statistical analyses were
performed using IBM SPSS Statistical Software (release 19.0; SPSS, Inc., Chi-
cago, IL).
RESULTS
The MIC results for the isolates tested are summarized in
Table 1. One isolate, R5717, displayed a CPT MIC value of
0.25 g/ml, while the other three isolates displayed a MIC
value of 0.5 g/ml. The first two isolates, R5717 and R5563,
were confirmed to be non-hVISA and non-VISA by population
analysis and vancomycin susceptibility testing and displayed a
DAP MIC value of 2 g/ml. Isolate R5995, a VISA strain





R5717 0.25 2 2
T96 0.25 8 4–8
T96 M NAc 8 8
R5563 0.5 2 2
T96 0.5 8 4
T96 M NA 8 NA
R5995 (VISA) 0.5 4 4
T96 0.5 4 4
T96 M NA 16 NA
R5996 (hVISA) 0.5 4 4
T96 0.5 8–16 4–8
T96 M NA 8–16 16
a T96, overall bacterial population at 96 h; T96 M, mutant bacterial population
at 96 h.
b CPT was used at 600 mg q12h.
c NA, no resistant mutants recovered.
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(ratio with Mu3, 1.23), and R5996, an hVISA strain (ratio with
Mu3, 1.15), both displayed a DAP MIC value of 4 g/ml.
The observed PK parameter values were within 12% of the
target values for both drugs. For CPT, the observed fCmax
values were 13.77 to 15 g/ml (goal, 15.2 g/ml) and the
observed t1/2 values were 2.25 to 2.47 h (goal, 2.3 h). The free
time above the MIC (fTMIC) was maintained for 100% of
the 12-h dosing interval for R5717 and 95% (11.4 h) for the
other three isolates. The observed fCmax and t1/2 values were
8.65 to 8.84 g/ml and 7.2 to 8.8 h for DAP6 (goal fCmax, 7.9
g/ml; t1/2, 8 h). The observed fAUC for DAP6 was approxi-
mately 108.7 g-h/ml, corresponding to fAUC/MIC ratios of
54 and 27 for isolates with DAP MIC values of 2 and 4 g/ml,
respectively. DAP10 (goal fCmax, 13.17 g/ml; t1/2, 8 h) pro-
duced values of 13.59 g/ml and 7.62 h for fCmax and t1/2,
respectively. The observed fAUC for DAP10 was approxi-
mately 149.4 g-h/ml, corresponding to fAUC/MIC ratios of
75 and 37 for isolates with DAP MIC values of 2 and 4 g/ml,
respectively.
The quantitative changes in log10 CFU/ml are displayed in
Fig. 1A to D. CPT displayed sustained bactericidal activity
against 3 of the 4 strains, with overall decreases of 3.1 log10
CFU/ml (R5717), 2.5 log10 CFU/ml (R5563), 6.38 log10
CFU/ml (R5995), and 5.77 log10 CFU/ml (R5996) at 96 h. No
mutants of any of the strains with elevated CPT MIC values
were recovered, and the overall population MIC value did not
change at 96 h (Table 1). The DAP6 regimen produced initial
bactericidal activity against R5995 and R5996 and reductions
in cell titers of 1.8 and 2.5 log10 for R5563 and R5717, respec-
tively; however, this activity was not sustained and substantial
regrowth of all four strains occurred. Under exposure to the
DAP6 simulated regimen, the MIC values of the overall pop-
ulation increased from 2 to 8 g/ml for R5717 and R5563 and
from 4 to 8 to 16 g/ml for R5996. Mutants of R5717/R5563
and R5995/R5996 displaying increased DAP MIC values of 8
and 16 g/ml, respectively, were recovered. At 96 h, reductions
in viable counts were significantly greater with CPT than DAP6
for all four strains (P  0.008).
The simulated regimen of DAP10 displayed a dose-depen-
dent increase in activity compared to DAP6. DAP10 was ini-
tially bactericidal against all four isolates. Regrowth of R5996
and R5717 occurred, with changes at 96 h of 1.8 and 0.7
log10 CFU/ml, respectively, versus the baseline. Mutants of
both of these strains with DAP MIC values of 16 and 8 g/ml,
FIG. 1. Activities of CPT, DAP6, and DAP10 against R5717 (A), R5563 (B), R5995 (VISA) (C), and R5996 (hVISA) (D). Closed circles,
growth control; open circles, CPT at 600 mg q12h; closed triangles, DAP6; open triangles, DAP10. Error bars are standard deviations of 2
independent experiments.
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respectively, were recovered. At 96 h, decreases in bacterial
counts for the DAP10 regimen were 1.2 log10 CFU/ml for
R5995 and 2.9 log10 CFU/ml for R5563. Mutants of neither of
these strains were recovered during exposure to the DAP10
regimen. At 96 h, CPT resulted in reductions in viable counts
of R5717 (P 	 0.001), R5995 (P  0.001), and R5996 (P 	
0.001) significantly greater than those obtained with DAP10.
DISCUSSION
Although DNS S. aureus remains rare, when encountered as
the cause of a clinical infection, it presents a treatment chal-
lenge, as optimal therapy is undefined (35). Recommended
treatment options for infections caused by DNS S. aureus that
also displays reduced susceptibility to vancomycin are limited
to a small number of agents (if the strain is still susceptible)
such as linezolid, quinupristin-dalfopristin, trimethoprim-sul-
famethoxazole, and telavancin (19). Since DNS infections oc-
cur most commonly in patients with complicated deep-seated
infections such as osteomyelitis, septic arthritis, and endocar-
ditis, the optimal therapy to treat these infections would be an
agent that is both bactericidal and relatively safe for longer
treatment durations (3, 35).
In the present study, we examined the activity of CPT
against four DNS MRSA strains, including an hVISA and a
VISA strain. CPT displayed sustained bactericidal activity
against three strains and achieved a sustained decrease in the
bacterial counts of the fourth of 2.5 log10 CFU/ml, correspond-
ing to a fTMIC of 95 to 100%. During this experiment, no
CPT-resistant mutants were recovered. In addition, CPT dis-
played enhanced activity with a greater than 5.5 log10 CFU/ml
decrease in the colony counts of the two strains also displaying
decreased susceptibility to vancomycin. This enhanced activity
may be clinically relevant, because decreased DAP susceptibil-
ity has been noted in some VISA strains (9). In addition to its
bactericidal activity, CPT appears to have a safety profile sim-
ilar to that of other cephalosporins based on data from its
clinical trials (6–8, 41). The combination of bactericidal activity
and a favorable safety profile could make CPT a valuable
potential option to treat MRSA infections, including those
caused by DNS MRSA. We also observed variable activity of
DAP at 6 and 10 mg/kg/day against the 4 DNS MRSA strains
tested. DAP displayed a dose-dependent effect against all 4
strains tested. A DAP ƒAUC/MIC ratio of 56 to 222 is required
for bactericidal activity (38). The ƒAUC/MICs achieved were
in this range for DAP at 10 mg/kg versus R57175 and R5563 at
75, and sustained bactericidal activity was observed for R5563.
In addition, exposure to DAP at 6 and 10 mg/kg/day produced
mutants against 4 and 2 of the strains tested, respectively. The
variable activity of high-dose DAP in vitro against DNS MRSA
is consistent with previous reports from our laboratory (28).
Although the exact mechanisms of DNS in S. aureus have yet
to be clearly elucidated, several changes in the cell membrane
and surface have been associated with these strains. S. aureus
strains with elevated DAP MIC values often display increased
cell wall thickness, an increased cell membrane surface charge
(causing repulsion of the DAP-Ca2 complex), and changes in
membrane fluidity (16, 21, 36). As CPT acts via the PBPs,
including PBP2a in S. aureus, these phenotypic changes would
not be expected to have a large effect, if any, on the activity of
CPT (23, 40). The bactericidal activity and magnitude of the
colony count decrease in this study are similar to those of a
previously published study with a similar hollow-fiber model
examining the activity of CPT against six S. aureus strains that
were DAP susceptible, suggesting that the addition of DNS has
little effect on CPT activity (39). Of these six strains, two also
had decreased susceptibility to vancomycin with an hVISA
phenotype. CPT displayed enhanced activity against one
hVISA strain, R1629, killing to the limit of detection. For the
other hVISA strain, regrowth occurred during exposure to the
CPT regimen and this was explained by the higher CPT MIC
value of 2 g/ml and the heterogeneous population analysis
profile.
Possible limitations of this study include its short duration,
inoculum amounts, and the use of only one DNS strain each
displaying the hVISA or VISA phenotype. As stated previ-
ously, most infections with DNS S. aureus require antibiotic
treatment for long durations. It is therefore possible that the
study period of 96 h (4 days) is not sufficient to elicit what the
full antibiotic and DNS S. aureus interaction would be under
longer exposures. The bacterial inoculum utilized for this study
of 7 log10 CFU/ml is moderate compared to some infections
typically associated with DNS S. aureus infections such as in-
fective endocarditis. While the CPT MIC value range of strains
utilized was 0.25 to 0.5 g/ml, the CPT fTMIC would be
approximately 80% of the dosing interval for strains with a
CPT MIC value of 1 g/ml, easily exceeding the CPT fTMIC
target of 45% for Gram-positive organisms (1). In this study,
CPT displayed enhanced activity against the two DNS S. aureus
strains also displaying an hVISA or VISA phenotype. Because
there was only one strain of each type, the ability to extrapolate
these results to other DNS S. aureus strains displaying de-
creased vancomycin susceptibility is limited.
In conclusion, CPT has the potential to provide a new ther-
apeutic option for treating DNS MRSA infections, as it is a
relatively well-tolerated antibiotic which could be more suit-
able for longer treatment durations while providing bacteri-
cidal activity. This is the first study evaluating the activity of
CPT against DNS MRSA in an in vitro PK/PD model. CPT
activity appeared to be enhanced for DNS S. aureus strains also
displaying the hVISA or VISA phenotype. Further study of
this enhanced activity and the efficacy of CPT for treating DNS
S. aureus infections is warranted.
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